Drug firms told to strengthen monitoring of medicine side effects

India's drug regulator has mandated pharmaceutical companies to establish robust systems for tracking and reporting adverse drug reactions. This directive, stemming from Schedule M of the Drugs and Cosmetics Rules, reinforces the critical need for post-marketing surveillance to ensure patient safety. The move aligns with a global push for real-world safety data to identify rare or delayed side effects.